Scienture Holdings, Inc. (SCNX) 已成功拓展其旗舰产品Rezenopy™的商业覆盖范围。该产品是当前获得美国食品药品监督管理局（FDA）批准的最高剂量纳洛酮鼻喷雾剂。通过达成一系列集团采购组织（GPO）协议，公司显著提升了这款关键药物的市场可及性。
此次合作将直接惠及美国境内超过5,000家医疗机构，包括医院、诊所和社区健康中心等。此举旨在确保更多有需要的人群能够及时获得这种高效的阿片类药物过量逆转疗法。Rezenopy™的高剂量特性为其在紧急情况下快速起效提供了保障，对应对阿片危机具有重要价值。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.